Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer



Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH Ingles
et al (show 18 more authors) (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. ANNALS OF ONCOLOGY, 29 (9). 1918 - 1925.

[img] Text
Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.pdf - Published Version

Download (721kB)
Item Type: Article
Uncontrolled Keywords: phase 1, m-TORC1/m-TORC2 inhibitor, combination therapy, ovarian cancer, squamous non-small-cell lung cancer
Depositing User: Symplectic Admin
Date Deposited: 30 Jan 2019 14:46
Last Modified: 09 Jan 2021 09:17
DOI: 10.1093/annonc/mdy245
Open Access URL: https://doi.org/10.1093/annonc/mdy245
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3027571